English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Tyroid-stimulatin hormone (TSH) - producing pituitary adenomas known as thyrotropinomas or TSHomas account for a small percentage of pituitary tumors [1]. Approximately 30% of them co-secrete growth hormone (GH), Prolactin, or αGSU of TSH [2]. We introduce a patient with a 12 years follow-up at our center with medical treatment by long-acting somatostatin analogues (SSA) due to rejected surgery. Along the treatment there is a scape with a secondary production of GH without image changes at the MRIs. We suggest a progressively acquired resistance to the medical treatment.

TSH and GH Producing Macroadenoma. Escape to Control with Long-Acting Somatostatin Analogues (SSA) After 12 Years Follow-Up. About A Case